3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Mantle-Cell
39
Waldenstrom Macroglobulinemia
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
14
Recurrence
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia
9
Lymphoma, B-Cell
8
Lymphoma
8
Neoplasms
7
Lymphoma, Non-Hodgkin
5
Leukemia, Prolymphocytic
4
Hodgkin Disease
4
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Leukemia, B-Cell
3
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Glioblastoma
2
Chromosome 17 deletion
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Primary Central Nervous System Lymphoma (PCNSL)
1
Interventions
Rituximab
15
Cyclophosphamide
15
Peripheral Blood Stem Cell Transplantation
14
fludarabine phosphate
11
Whole-Body Irradiation
11
Mycophenolic Acid
8
Etoposide
8
Methotrexate
7
Filgrastim
7
Cyclosporine
7
Lenalidomide
6
Dexamethasone
6
Busulfan
6
Tacrolimus
5
Radiotherapy
5
Cytarabine
5
Carboplatin
5
Thiotepa
4
Melphalan
4
Transplantation
3
Therapeutics
3
Granulocyte Colony-Stimulating Factor
3
Flow Cytometry
3
Calcium Dobesilate
3
Bortezomib
3
Antilymphocyte Serum
3
pegfilgrastim
2
etoposide phosphate
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Intraocular Lymphoma
×
ibrutinib
×
Clear all
NCT02542514
2022-04-14
iLOC
The Lymphoma Academic Research Organisation
Phase 2
Completed
52 enrolled